Zhaobin Kuang
ABSTRACT
Computational Drug Repositioning (CDR) is the task of discovering potential new indications for existing drugs by mining large-scale heterogeneous drug-related data sources. Leveraging the patient-level temporal ordering information between numeric physiological measurements and various drug prescriptions provided in Electronic Health Records (EHRs), we propose a Continuous Self-controlled Case Series (CSCCS) model for CDR. As an initial evaluation, we look for drugs that can control Fasting Blood Glucose (FBG) level in our experiments. Applying CSCCS to the Marshfield Clinic EHR, well-known drugs that are indicated for controlling blood glucose level are rediscovered. Furthermore, some drugs with recent literature support for the potential effect of blood glucose level control are also identified.
- Ted T Ashburn and Karl B Thor. Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 2004.Google Scholar
- MR Hurle, L Yang, Q Xie, DK Rajpal, P Sanseau, and P Agarwal. Computational drug repositioning: from data to therapeutics. Clinical Pharmacology & Therapeutics, 2013.Google Scholar
- Jiao Li, Si Zheng, Bin Chen, Atul J. Butte, S. Joshua Swamidass, and Zhiyong Lu. A survey of current trends in computational drug repositioning. Briefings in Bioinformatics, 2015.Google Scholar
- Justin Lamb. The connectivity map: a new tool for biomedical research. Nature Reviews Cancer, 2007.Google Scholar
- Michael Kuhn, Monica Campillos, Ivica Letunic, Lars Juhl Jensen, and Peer Bork. A side effect resource to capture enotypic effects of drugs. Molecular Systems Biology, 2010.Google Scholar
- Yanbin Liu, Bin Hu, Chengxin Fu, and Xin Chen. Dcdb: drug combination database. Bioinformatics, 2010.Google Scholar
- Craig Knox, Vivian Law, Timothy Jewison, Philip Liu, Son Ly, Alex Frolkis, Allison Pon, Kelly Banco, Christine Mak, Vanessa Neveu, et al. Drugbank 3.0: a comprehensive resource for omics research on drugs. Nucleic Acids Research, 2011.Google Scholar
- Hua Xu, Melinda C Aldrich, Qingxia Chen, Hongfang Liu, Neeraja B Peterson, Qi Dai, Mia Levy, Anushi Shah, Xue Han, Xiaoyang Ruan, Min Jiang, Ying Li, Jamii St Julien, Jeremy Warner, Carol Friedman, Dan M Roden, and Joshua C Denny. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. Journal of the American Medical Informatics Association, 2014.Google ScholarCross Ref
- Shawn E Simpson, David Madigan, Ivan Zorych, Martijn J Schuemie, Patrick B Ryan, and Marc A Suchard. Multiple self controlled case series for large scale longitudinal observational databases. Biometrics, 2013.Google Scholar
- Vito MR Muggeo. Estimating regression models with unknown break points. Statistics in Medicine, 2003.Google Scholar
- Stanley Xu, Chan Zeng, Sophia Newcomer, Jennifer Nelson, and Jason Glanz. Use of fixed effects models to analyze self-controlled case series data in vaccine safety studies. Journal of Biometrics & Biostatistics, 2012.Google ScholarCross Ref
- Prakash M Nadkarni. Drug safety surveillance using de-identified EMR and claims data: issues and challenges. Journal of the American Medical Informatics Association, 2010.Google ScholarCross Ref
- PB Ryan. Establishing a drug era persistence window for active surveillance. White Papers, 2010.Google Scholar
- Robert Tibshirani. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society. Series B (Methodological), 1996.Google Scholar
- Edward W Frees. Longitudinal and panel data: analysis and applications in the social sciences. Cambridge University Press, 2004.Google ScholarCross Ref
- AACE. Management of common comorbidities of diabetes. http://outpatient.aace.com/type-2-diabetes/management-of-common-comorbidities-of-diabetes. (Visited on 02/06/2016).Google Scholar
- RM Daniel, SN Cousens, De BL Stavola, MG Kenward, and JAC Sterne. Methods for dealing with time dependent confounding. Statistics in Medicine, 2013.Google Scholar
- Stephanie J Reisinger, Patrick B Ryan, Donald J O'Hara, Gregory E Powell, Jeffery L Painter, Edward N Pattishall, and Jonathan A Morris. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. Journal of the American Medical Informatics Association, 2010.Google ScholarCross Ref
- Jean-Louis Montastruc, Agnès Sommet, Haleh Bagheri, and Maryse Lapeyre-Mestre. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. British Journal of Clinical Pharmacology, 2011.Google ScholarCross Ref
- OMOP. Ground truth for monitoring health outcomes of interest. http://omop.org/sites/default/files/ground%20truth.pdf, 2015. (Visited on 09/28/2015).Google Scholar
- Martin J Wainwright. Sharp thresholds for high-dimensional and noisy recovery of sparsity using l1-constrained quadratic programming. IEEE Transactions on Information Theory, 2009. Google ScholarDigital Library
- DiabetesInControl. Drugs that can affect blood glucose levels. http://www.diabetesincontrol.com/wp-content/uploads/2010/07/www.diabetesincontrol.com_images_tools_druglistaffectingbloodglucose.pdf, 2015. (Visited on 09/28/2015).Google Scholar
- Patrick J Lustman, Monique M Williams, Gregory S Sayuk, Billy D Nix, and Ray E Clouse. Factors influencing glycemic control in type 2 diabetes during acute-and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care, 2007.Google Scholar
- Jose A Vazquez and Jack D Sobel. Fungal infections in diabetes. Infectious Disease Clinics of North America, 1995.Google Scholar
- ADA. Skin complications. http://www.diabetes.org/living-with-diabetes/complications/skin-complications.html?referrer=https://www.google.com/. (Visited on 01/19/2016).Google Scholar
- CDC. Smoking and diabetes. http://www.cdc.gov/tobacco/campaign/tips/diseases/diabetes.html. (Visited on 01/19/2016).Google Scholar
- Emmanuelle Vermes, Anique Ducharme, Martial G Bourassa, Myriam Lessard, Michel White, and Jean-Claude Tardif. Enalapril reduces the incidence of diabetes in patients with chronic heart failure insight from the studies of left ventricular dysfunction (solvd). Circulation, 2003.Google Scholar
- Taner Damci, Serkan Tatliagac, Zeynep Osar, and Hasan Ilkova. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. European Journal of Internal Medicine, 2003.Google ScholarCross Ref
- Pitchai Balakumar, Rajavel Varatharajan, Ying Nyo, Raja Renushia, Devarajan Raaginey, Ann Oh, Shaikh Akhtar, Mani Rupeshkumar, Karupiah Sundram, and Sokkalingam A Dhanaraj. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacological Research, 2014.Google ScholarCross Ref
- Bacon F Chow and Howard H Stone. The relationship of vitamin b12 to carbohydrate metabolism and diabetes mellitus. The American Journal of Clinical Nutrition, 1957.Google ScholarCross Ref
- Rose Zhao-Wei Ting, Cheuk Chun Szeto, Michael Ho-Ming Chan, Kwok Kuen Ma, and Kai Ming Chow. Risk factors of vitamin b12 deficiency in patients receiving metformin. Archives of Internal Medicine, 2006.Google Scholar
- Murat Kesim, Ahmet Tiryaki, Mine Kadioglu, Efnan Muci, Nuri Ihsan Kalyoncu, and Ersin Yaris. The effects of sertraline on blood lipids, glucose, insulin and hba1c levels: A prospective clinical trial on depressive patients. Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences, 2011.Google Scholar
- Junichi Kodama, Shigehiro Katayama, Kiyoshi Tanaka, Akira Itabashi, Shyoji Kawazu, and Jun Ishii. Effect of captopril on glucose concentration: possible role of augmented postprandial forearm blood flow. Diabetes Care, 1990.Google Scholar
- Tetsuo Satoh, Shuichi Hara, Midori Takashima, and Haruo Kitagawa. Hyperglycemic effect of hydralazine in rats. Journal of Pharmacobio-Dynamics, 1980.Google ScholarCross Ref
- FDA. Consumer updates: FDA expands advice on statin risks. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm, 2014. (Visited on 09/28/2015).Google Scholar
- Dilys J Freeman, John Norrie, Naveed Sattar, R Dermot G Neely, Stuart M Cobbe, Ian Ford, Christopher Isles, A Ross Lorimer, Peter W Macfarlane, James H McKillop, et al. Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the west of scotland coronary prevention study. Circulation, 2001.Google Scholar
- Aleesa A Carter, Tara Gomes, Ximena Camacho, David N Juurlink, Baiju R Shah, and Muhammad M Mamdani. Risk of incident diabetes among patients treated with statins: population based study. BMJ, 2013.Google ScholarCross Ref
- Jay D Amsterdam, Justine Shults, Nancy Rutherford, and Stanley Schwartz. Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus. Neuropsychobiology, 2006.Google ScholarCross Ref
- Joep HG Scholl, Rike van Eekeren, and Eugène P van Puijenbroek. Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients. British Journal of Clinical Pharmacology, 2015.Google ScholarCross Ref
- Khanh vinh quoc Luong and Lan Thi Hoang Nguyen. The impact of thiamine treatment in the diabetes mellitus. Journal of Clinical Medicine Research, 2012.Google ScholarCross Ref
- GLJ Page, David Laight, and MH Cummings. Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease. International Journal of Clinical Practice, 2011.Google ScholarCross Ref
- T Inukai, Y Inukai, R Matsutomo, K Okumura, K Takanashi, K Takebayashi, K Tayama, Y Aso, and Y Takemura. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. The Journal of International Medical Research, 2004.Google ScholarCross Ref
- FDA. Premarin (conjugated estrogens tablets, usp). http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/004782s147lbl.pdf. (Visited on 02/08/2016).Google Scholar
- Paul Samuel. Treatment of hypercholesterolemia with neomycin-a time for reappraisal. New England Journal of Medicine, 1979.Google ScholarCross Ref
- YA Kesaniemi and Scott M Grundy. Turnover of low density lipoproteins during inhibition of cholesterol absorption by neomycin. Arteriosclerosis, Thrombosis, and Vascular Biology, 1984.Google Scholar
- David JA Jenkins, Cyril WC Kendall, Maryam Hamidi, Edward Vidgen, Dorothea Faulkner, Tina Parker, Nalini Irani, Thomas MS Wolever, Ignatius Fong, Peter Kopplin, et al. Effect of antibiotics as cholesterol-lowering agents. Metabolism, 2005.Google Scholar
- David Madigan, Shawn Simpson, Wei Hua, Antonio Paredes, Bruce Fireman, and Malcolm Maclure. The self-controlled case series: Recent developments. Submitted, 2015. URL http://www.stat.columbia.edu/ madigan/PAPERS/DrugSafety.pdf.Google Scholar
Index Terms
- Computational Drug Repositioning Using Continuous Self-Controlled Case Series
Recommendations
Pharmacovigilance via Baseline Regularization with Large-Scale Longitudinal Observational Data
KDD '17: Proceedings of the 23rd ACM SIGKDD International Conference on Knowledge Discovery and Data MiningSeveral prominent public health incidents that occurred at the beginning of this century due to adverse drug events (ADEs) have raised international awareness of governments and industries about pharmacovigilance (PhV), the science and activities to ...
Adverse drug reaction discovery from electronic health records with deep neural networks
CHIL '20: Proceedings of the ACM Conference on Health, Inference, and LearningAdverse drug reactions (ADRs) are detrimental and unexpected clinical incidents caused by drug intake. The increasing availability of massive quantities of longitudinal event data such as electronic health records (EHRs) has redefined ADR discovery as a ...
Temporality and Context for detecting adverse drug reactions from longitudinal data
This paper introduces a method for mining co-occurring events from longitudinal data, and applies this method to detecting adverse drug reactions (ADRs) from patient data. Electronic health records are richer than older data sources (such as spontaneous ...
Comments